U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H17N3O7S2
Molecular Weight 427.4549
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEFOXITIN

SMILES

CO[C@]1(C(=O)N2C(=C(COC(=N)O)CS[C@]12[H])C(=O)O)N=C(Cc3cccs3)O

InChI

InChIKey=WZOZEZRFJCJXNZ-ZBFHGGJFSA-N
InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/cefoxitin.html

Cefoxitin is a cephamycin antibiotic often grouped with the second-generation cephalosporins. It is active against a broad range of gram-negative bacteria including anaerobes. The methoxy group in the 7a position provides cefoxitin with a high degree of stability in the presence of beta-lactamases, both penicillinases and cephalosporinases, of gram-negative bacteria. The bactericidal action of cefoxitin results from inhibition of cell wall synthesis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Escherichia coli growth
Target ID: Klebsiella pneumoniae growth
Target ID: P08506
Gene ID: 945455.0
Gene Symbol: dacC
Target Organism: Escherichia coli (strain K12)
Target ID: P0AEB2
Gene ID: 945222.0
Gene Symbol: dacA
Target Organism: Escherichia coli (strain K12)
Target ID: P0AFI5
Gene ID: 946662.0
Gene Symbol: pbpG
Target Organism: Escherichia coli (strain K12)
Target ID: P02919
Gene ID: 944843.0
Gene Symbol: mrcB
Target Organism: Escherichia coli (strain K12)
Target ID: P0A3M6
Gene ID: 933948.0
Gene Symbol: penA
Target Organism: Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
8.0 nM [IC50]
Target ID: Q8DR59
Gene ID: 934791.0
Gene Symbol: pbpA
Target Organism: Streptococcus pneumoniae (strain ATCC BAA-255 / R6)
6.8 nM [IC50]
Target ID: 933569.0
Gene Symbol: pbp2a
2.4 nM [IC50]
Target ID: 934893.0
Gene Symbol: pbp1b
0.145 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Cefoxitin

Approved Use

Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli, Klebsiella species, Proteus mirabilis, Morganella morganii, Proteus vulgaris and Providencia species (including P. rettgeri). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli, Klebsiella species, Bacteroides species including Bacteroides fragilis, and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli, Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, Peptostreptococcus species and Streptococcus agalactiae. Cefoxitin for injection, like cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when Cefoxitin for injection is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae, Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Escherichia coli, Proteus mirabilis, Klebsiella species, Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, and Peptostreptococcus species.

Launch Date

1.26826565E12
Curative
Cefoxitin

Approved Use

Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli, Klebsiella species, Proteus mirabilis, Morganella morganii, Proteus vulgaris and Providencia species (including P. rettgeri). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli, Klebsiella species, Bacteroides species including Bacteroides fragilis, and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli, Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, Peptostreptococcus species and Streptococcus agalactiae. Cefoxitin for injection, like cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when Cefoxitin for injection is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae, Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Escherichia coli, Proteus mirabilis, Klebsiella species, Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, and Peptostreptococcus species.

Launch Date

1.26826565E12
Curative
Cefoxitin

Approved Use

Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae, other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli, Klebsiella species, Proteus mirabilis, Morganella morganii, Proteus vulgaris and Providencia species (including P. rettgeri). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli, Klebsiella species, Bacteroides species including Bacteroides fragilis, and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli, Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, Peptostreptococcus species and Streptococcus agalactiae. Cefoxitin for injection, like cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when Cefoxitin for injection is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae, Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli, Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis]), Escherichia coli, Proteus mirabilis, Klebsiella species, Bacteroides species including B. fragilis, Clostridium species, Peptococcus niger, and Peptostreptococcus species.

Launch Date

1.26826565E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
24 μg/mL
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
33.5 μg × h/mL
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.67 h
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
27%
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
CEFOXITIN plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 g single, intramuscular
Dose: 2 g
Route: intramuscular
Route: single
Dose: 2 g
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Hoigne's syndrome...
AEs leading to
discontinuation/dose reduction:
Hoigne's syndrome (1 patient)
Sources:
12 g 1 times / day multiple, intravenous
Highest studied dose
Dose: 12 g, 1 times / day
Route: intravenous
Route: multiple
Dose: 12 g, 1 times / day
Sources:
unhealthy, 22 years
n = 1
Health Status: unhealthy
Condition: bacterial endocarditis
Age Group: 22 years
Sex: M
Population Size: 1
Sources:
2 g 3 times / day multiple, intravenous
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 45 years
n = 1
Health Status: unhealthy
Age Group: 45 years
Sex: F
Population Size: 1
Sources:
Disc. AE: Hemolytic anemia...
AEs leading to
discontinuation/dose reduction:
Hemolytic anemia (1 patient)
Sources:
1 g 4 times / day multiple, intravenous
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
unhealthy, 77 years
n = 1
Health Status: unhealthy
Condition: peritonitis
Age Group: 77 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Hemolytic anemia, Pancytopenia...
AEs leading to
discontinuation/dose reduction:
Hemolytic anemia (1 patient)
Pancytopenia (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Hoigne's syndrome 1 patient
Disc. AE
2 g single, intramuscular
Dose: 2 g
Route: intramuscular
Route: single
Dose: 2 g
Sources:
unhealthy, 17 years
n = 1
Health Status: unhealthy
Age Group: 17 years
Sex: F
Population Size: 1
Sources:
Hemolytic anemia 1 patient
Disc. AE
2 g 3 times / day multiple, intravenous
Dose: 2 g, 3 times / day
Route: intravenous
Route: multiple
Dose: 2 g, 3 times / day
Sources:
unhealthy, 45 years
n = 1
Health Status: unhealthy
Age Group: 45 years
Sex: F
Population Size: 1
Sources:
Hemolytic anemia 1 patient
Disc. AE
1 g 4 times / day multiple, intravenous
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
unhealthy, 77 years
n = 1
Health Status: unhealthy
Condition: peritonitis
Age Group: 77 years
Sex: M
Population Size: 1
Sources:
Pancytopenia 1 patient
Disc. AE
1 g 4 times / day multiple, intravenous
Dose: 1 g, 4 times / day
Route: intravenous
Route: multiple
Dose: 1 g, 4 times / day
Sources:
unhealthy, 77 years
n = 1
Health Status: unhealthy
Condition: peritonitis
Age Group: 77 years
Sex: M
Population Size: 1
Sources:
PubMed

PubMed

TitleDatePubMed
Ceftizoxime-induced hemolysis due to immune complexes: case report and determination of the epitope responsible for immune complex-mediated hemolysis.
1999 Mar
Occurrence of metronidazole and imipenem resistance among Bacteroides fragilis group clinical isolates in Hungary.
2001
Improved methods for detection of methicillin-resistant Staphylococcus aureus.
2001 Apr
Prevalence and analysis of risk factors for infections caused by resistant Escherichia coli strains in Anhui, China.
2001 Aug
Natural antibiotic susceptibility of strains of the Enterobacter cloacae complex.
2001 Dec
A novel metallo-beta-lactamase, Mbl1b, produced by the environmental bacterium Caulobacter crescentus.
2001 Dec 14
Plasmid-mediated and inducible cephalosporinase DHA-2 from Klebsiella pneumoniae.
2001 Feb
Inactivation of Aeromonas hydrophila metallo-beta-lactamase by cephamycins and moxalactam.
2001 Jul
Detection of beta-lactamase-mediated resistance.
2001 Jul
Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents.
2001 Jul
Laparoscopic management of gallstone ileus.
2001 Jul-Sep
Antimicrobial resistance of Shigella sonnei in Korea during the last two decades.
2001 Mar
Cephalosporins in surgical prophylaxis.
2001 Nov
Molecular mechanisms of cefoxitin resistance in Escherichia coli from the Toronto area hospitals.
2001 Sep-Oct
Probing substrate binding to metallo-beta-lactamase L1 from Stenotrophomonas maltophilia by using site-directed mutagenesis.
2002
Increase in resistance to new fluoroquinolones from 1998 to 2001 in the Bacteroides fragilis group.
2002 Dec
Antibacterial activity of moxifloxacin against periodontal anaerobic pathogens involved in systemic infections.
2002 Dec
Mycobacterium fortuitum complex endocarditis-case report and literature review.
2002 Feb
[Identification of plasmid-encoded cephalosporinase ACC-1 among various enterobacteria (Klebsiella pneumoniae, Proteus mirabilis, Salmonella) isolated from a Tunisian hospital (Sfax 997-2000)].
2002 Feb
Clinical review: bacteremia caused by anaerobic bacteria in children.
2002 Jun
Characterization of cefotaxime-resistant Escherichia coli isolates from a nosocomial outbreak at three geriatric hospitals.
2002 Jun
Outbreak of multidrug-resistant Salmonella newport--United States, January-April 2002.
2002 Jun 28
The ACT-1 plasmid-encoded AmpC beta-lactamase is inducible: detection in a complex beta-lactamase background.
2002 Mar
[Genotypic exploration of a hospital neonatal outbreak due to Klebsiella pneumoniae producing extended-spectrum-betalactamase].
2002 May
Comparison of screening methods for TEM- and SHV-derived extended-spectrum beta-lactamase detection.
2002 Nov
Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection.
2002 Nov
Natural antibiotic susceptibility of Enterobacter amnigenus, Enterobacter cancerogenus, Enterobacter gergoviae and Enterobacter sakazakii strains.
2002 Sep
Klebsiella and enterobacter: antibiotic resistance and treatment implications.
2002 Sep
A clinical strain of Escherichia coli possessing CMY-2 plasmid-mediated amp C beta-lactamase: an emerging concern in pediatrics?
2002 Winter
Pelvic inflammatory disease: how should it be managed?
2003 Feb
Beta-lactamase characterization in Escherichia coli isolates with diminished susceptibility or resistance to extended-spectrum cephalosporins recovered from sick animals in Spain.
2003 Summer
Patents

Sample Use Guides

In Vivo Use Guide
Adults The usual adult dosage range is 1 gram to 2 grams every six to eight hours.
Route of Administration: Intravenous
CEFOXITIN inhibited Mycobacterium fortuitum growth with MIC 32 ug/ml
Name Type Language
CEFOXITIN
INN   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
J01DC01
Code English
CEFOXITIN [WHO-DD]
Common Name English
(6R,7S)-3-(HYDROXYMETHYL)-7-METHOXY-8-OXO-7-(2-(2-THIENYL)ACETAMIDO)-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID CARBAMATE (ESTER)
Systematic Name English
CEFOXITIN [USAN]
Common Name English
CEFOXITIN [VANDF]
Common Name English
CEFOXITIN [USP-RS]
Common Name English
CEFOXITIN [ORANGE BOOK]
Common Name English
CEFOXITIN [MI]
Common Name English
CEFOXITIN [INN]
Common Name English
Classification Tree Code System Code
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
LIVERTOX 167
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
WHO-VATC QJ01DC01
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000175488
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NCI_THESAURUS C357
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
NDF-RT N0000011161
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
WHO-ATC J01DC01
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL996
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
MERCK INDEX
M3208
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY Merck Index
DRUG CENTRAL
550
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
ECHA (EC/EINECS)
252-641-2
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
CAS
35607-66-0
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
WIKIPEDIA
CEFOXITIN
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
LACTMED
Cefoxitin
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
USP_CATALOG
1098107
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY USP-RS
INN
3397
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
EVMPD
SUB07409MIG
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
MESH
D002440
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
RXCUI
2189
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY RxNorm
FDA UNII
6OEV9DX57Y
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
DRUG BANK
DB01331
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
NCI_THESAURUS
C61665
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
EPA CompTox
35607-66-0
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY
PUBCHEM
441199
Created by admin on Sat Jun 26 00:24:18 UTC 2021 , Edited by admin on Sat Jun 26 00:24:18 UTC 2021
PRIMARY